Researchers report that critically ill patients treated with tocilizumab show improved outcomes

Early results from the Remap-Cap trial show patients treated with tocilizumab were more likely to improve than those who received no immunomodulator (OR 1.87). These results are however based on a combined outcome and the relative contribution of each has not been analysed.

SPS commentary:

The analysis included data from 303 patients randomised to treatment with immune modulators (tocilizumab, sarilumab, anakinra or interferon) or no such treatment, on the first day of becoming seriously unwell and moving into intensive care. An independent data and safety monitoring board has recommended that the trial stop recruiting into the no immune modulator arm, based on these findings.

British Medical Journal